![Page 1: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/1.jpg)
![Page 2: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/2.jpg)
2
![Page 3: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/3.jpg)
3
![Page 4: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/4.jpg)
4
![Page 5: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/5.jpg)
5
AUG
OCT
SEP
![Page 6: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/6.jpg)
(5.7%)
6
![Page 7: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/7.jpg)
7
39.95.02.2
(3.4%)
![Page 8: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/8.jpg)
8
![Page 9: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/9.jpg)
9
![Page 10: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/10.jpg)
10
![Page 11: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/11.jpg)
11
![Page 12: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/12.jpg)
12
![Page 13: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/13.jpg)
13
![Page 14: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/14.jpg)
14
![Page 15: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/15.jpg)
15
![Page 16: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/16.jpg)
16
![Page 17: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/17.jpg)
17
Diabetes/Obesity
Rare diseases
Cancer
Autoimmune diseases
Others
B Beijing Hanmi
Pre-Clinical Phase 2 Phase 3Phase 1
LAPSGCG ComboHM14320Obesity/Diabetes/NASH
GBM Stem Cell TherapyHM21001Glioblastoma
AJOU Univ
LAPSTriple AgonistHM15211NASH
LAPSGCG AnalogHM15136Obesity/Congenital Hyperinsulinism
PD-1/CD47BH29XXTargeted Immuno-oncology
B
LAPSASBHM15450Mucopolysaccharidosis
LAPSGLP/GCGHM12525AObesity/Diabetes
LAPSIns/LAPSInsulin AnalogHM12460A/HM12470Diabetes
Pan-RAF InhibitorBelvarafenibSolid tumors
GENENTECH
PD-1/PD-L1BH2996HTargeted Immuno-oncology
B
EfpeglenatideLAPSExd4 AnalogObesity/Diabetes
SANOFI
EfpegsomatropinLAPShGHGH deficiency
Luminate®
Integrin inhibitor
DMEALLEGRO
BTK InhibitorHM71224Autoimmune disease
Pan-HER InhibitorPoziotinibSolid tumor
SPECTRUM
Rolontis™EflapegrastimNeutropenia
SPECTRUM
Oraxol™Paclitaxel+HM30181ASolid tumor
ATHENEX
PD-1/HER2BH2950Targeted Immuno-oncology
B
INNOVENT
FLT3 InhibitorHM43239
AML
TNF-α/IL-17BH1657Targeted Autoimmune diseases
B LAPSGLP-2 AnalogHM15912Short Bowel Syndrome
LAPSInsulin148HM12480Diabetes
LAPSInsulin ComboHM14220Diabetes
Luminate®
Integrin inhibitorRetinitis Pigmentosa
Oratecan™Irinotecan+HM30181ASolid tumor
Oradoxel™Docetaxel+HM30181ASolid tumor
ATHENEX
ATHENEX
A2AR antagonist
Solid tumor
LSD1 Inhibitor
SCLC, AML
SANOFI
![Page 18: PowerPoint 프레젠테이션 · 2019-10-29 · 17 Diabetes/Obesity Rare diseases Cancer Autoimmune diseases Others B Beijing Hanmi Pre-Clinical Phase 1 Phase 2 Phase 3 LAPSGCG Combo](https://reader031.vdocuments.mx/reader031/viewer/2022011816/5e758e79fb990f637772b5d7/html5/thumbnails/18.jpg)
18